Oral orforglipron could be more effective in reducing hemoglobin A1c and body weight, with no increased risk of hypoglycemia in patients with inadequately controlled type 2 diabetes.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
This week's research makes one thing clear: who someone is before they get sick — their relationships, their partner's health, the back of their eye — is doing a lot of work medicine is only beginning to account for.
Researchers urge caution in interpreting joint replacement predictors, noting that surgery reflects access and decision-making as well as disease biology.
A posthoc analysis of a phase 2b trial found favorable changes in DNA methylation–based aging biomarkers among patients with human immunodeficiency virus–associated lipohypertrophy.